European Notebook: U.S. Investors Tap Into Europe; New U.K. Pricing Scheme; Pfizer Dismayed By German Payers
Executive Summary
Europe's IPO window remains closed but the region still attracts U.S. investors; drug spending set to decline in Greece and Spain in 2014; Pfizer takes Bosulif off the German market because agreement on price unlikely with health insurers; no room for value-based pricing in the U.K.; European Parliament clears €80 billion in research funding under Horizon 2020.
You may also be interested in...
Egalet Lines Up Cash In Deal With Japan’s Shionogi Ahead Of IPO
The specialty pharma will receive $10 million upfront from Shionogi in exchange for rights to multiple oral abuse-deterrent hydrocodone opioid products. The Japanese pharma also agreed to buy $15 million in stock to close with Egalet’s IPO.
German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.
Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.